Sanofi

Sanofi-aventis

Elf Sanofi

Societe Anonyme Sanofi

Bernard Labeeuw

Robert Boigegrain

Danielle Gully

Jean-Charles Molimard

Francis JeanJean

Ali Salhi

Pierre Casellas

Samir Jegham

Patrick Gueule

Christian Congy

Dominique Olliero

Murielle Rinaldi

Daniel Floutard

Pierre Fraisse

Pierre Carayon

Gilles Roche

Ali Sahli

The invention relates to 2-acylamino-4-phenylthiazole derivatives of general formula (I): pharmaceutically acceptable acid-addition salts thereof, hydrates or solvates of such derivatives or such pharmaceutically acceptable acid addition salts, intermediates thereto, processes for the preparation thereof, and therapeutic application thereof.

2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof

The invention relates to compounds of the formula

Substituted 1-phenyl-3-pyrazolecarboxamides active on neurotensin receptors, their preparation and pharamaceutical compositions containing them

The invention relates to compounds of the formula: ##STR1## Compounds of the above formula have a great affinity for the neurotensin receptors.

Substituted 1-phenyl-3-pyrazolecarboxamides active on neurotensin

The invention relates to compounds of the formula: ##STR1## The compounds have great affinity for the neurotensin receptors.

This invention relates to intermediate compounds which are useful for making substituted 1-phenyl-3-pyrazolecarboxamides. The compounds of the invention have the formula: ##STR1## in which: R'.sub.2 and R'.sub.3 each independently represent a hydrogen, a (C.sub.1 -C.sub.6)alkyl, a (C.sub.3 -C.sub.8)cycloalkyl, a (C.sub.3 -C.sub.8)cycloalkylmethyl;

Hydrazine derivative compounds as intermediates for preparing

The invention relates to new substituted 1-phenyl-3-pyrazolecarboxamides having a great affinity for human neurotensin receptors, to a process for preparing them and to pharmaceutical compositions containing them as active principles. More particularly, this invention relates to the discovery that the affinity for neurotensin receptors, especially human neurotensin receptors, is increased by substituting the phenyl group of 1-phenyl-3-pyrazolecarboxamide compounds with particular groups.

The invention relates to substituted 1-naphyl-3-pyrazolecarboxamides of formula I: ##STR1## These compounds are useful for the treatment of neuropsychiatric disorders, especially those associated with a dysfunction of the dopaminergic systems.

Substituted 1-naphthyl-3-pyrazolecarboxamides which are active on

A compound of formula: ##STR1## in which R.sub.y represents a cyano or carboxymethyl group and its salts.

The invention relates to substituted 1-naphthyl-3-pyrazolecarboxamides of formula I: ##STR1## Application: These compounds are useful for the treatment of neuropsychiatric disorders, especially those associated with a dysfunction of the dopaminergic systems.

The invention relates to new propenone oxime ethers, a method of preparing them and pharmaceutical compositions containing them. Said new propenone oxime ethers have the formula ##STR1## in which Ar and Ar' each independently denotes a phenyl group non-substituted, mono or polysubstituted, a 9-anthryl group or a naphthyl group, a pyridyl, thienyl or furyl group;

Intermediates useful in preparing propenone oxime ethers

The present invention relates to novel cephalosporin derivatives with improved pharmacokinetics, corresponding to the formula: ##STR1## in which: R.sub.1, R.sub.2 and R.sub.3 represent a hydrogen atom, or R.sub.1 and R.sub.2 represent a hydrogen atom or a methyl group and R.sub.3 represents a carboxyl group, or ##STR2## form a cyclobutyl group and R.sub.3 represents a carboxyl group; and A and B are different and occupy the meta and para positions of the benzene ring, one representing a hydroxyl group and the other being selected from the groups ##STR3## and --NH--SO.sub.2 --Alk--NH.sub.2 in which Alk denotes a C.sub.2 -C.sub.4 lower alkylene group and also to the pharmaceutically acceptable salts and esters of the said derivatives. It further relates to a process for the preparation of such cephalosporins and to pharmaceutical compositions in which they are present.

Aromatic acid intermediates

The invention relates to new propenone oxime ethers, a method of preparing them and pharmaceutical compositions containing them. Said new propenone oxime ethers have the formula ##STR1## in which--Ar and Ar' each independentlyl denotes a phenyl group non-substituted, mono or polysubstituted, a 9-anthryl group or a naphthyl group, a pyridyl, thienyl or furyl group;

Growing community of inventors

Montpellier, France

Bernard Labeeuw